Northern Trust Corp Grows Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Northern Trust Corp lifted its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 43.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 384,157 shares of the biotechnology company's stock after purchasing an additional 116,086 shares during the period. Northern Trust Corp owned about 0.84% of Capricor Therapeutics worth $5,301,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after buying an additional 700,243 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Altium Capital Management LLC raised its stake in Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after purchasing an additional 429,000 shares during the last quarter. Black Diamond Financial LLC purchased a new position in Capricor Therapeutics in the 4th quarter valued at $3,833,000. Finally, Kennedy Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth $1,991,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.61 during midday trading on Monday, reaching $10.25. 1,665,784 shares of the stock were exchanged, compared to its average volume of 1,734,938. The stock has a market capitalization of $468.19 million, a P/E ratio of -9.67 and a beta of 0.85. The company has a 50 day simple moving average of $10.46 and a 200 day simple moving average of $13.33. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. During the same quarter in the prior year, the firm earned ($0.31) EPS. On average, research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CAPR has been the subject of a number of recent research reports. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Roth Capital initiated coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.